Pharmacokinetic and Pharmacology Evaluations for Cancer Patients
Ended Master IDIQ Awarded
- Federal agency
-
National Institutes of Health
- Awardees
- 5
- Task orders
- 14
- Obligated
- $1,180,979
Vehicle facts
- Opportunity
-
- N02CM6700011 Solicitation number
- Agency
-
- National Institutes of Health Department of Health and Human Services
- Combined task order value
-
- $1,180,979 Current, with exercised options
- $1,452,665 Potential, with all options
- Last date to order 100% complete
- Shared ceiling 12% used
- $9,900,000.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Institutes of Health established this Master IDIQ for preclinical pharmacokinetic and pharmacology evaluations of cancer-therapy agents on July 1, 2016, with a shared ceiling of $9.9 million, but ordering closed on June 30, 2021 — this vehicle is no longer accepting new task orders.
Fourteen task orders were issued under the vehicle, with the most recent award on April 16, 2021. The National Cancer Institute (within NIH) placed all 14 orders. Activity declined sharply after the initial years: 2016–2017 saw nine orders, but only one order was placed in 2018, three in 2019, and one in 2021. The combined potential value across all task orders is $1.5 million, with $1.2 million obligated (81% of potential).
Awarded work centers on preclinical pharmacokinetic studies in animal models and analytical support for drug-candidate assessment. Task orders include pharmacokinetic and bioavailability studies in mice and rats (using NSG mouse models), plasma and urine bioanalysis for anticancer compounds, and formulation testing for early-stage pharmacokinetic assessments. Most orders are firm-fixed-price or cost-no-fee arrangements with performance periods ranging from one to five years. Representative task-order values range from roughly $27,000 to $218,000 in ceiling value.
Competition is highly concentrated. University of Pittsburgh holds 50% of combined potential value across seven orders ($851 thousand). Mayo Clinic accounts for 39% across four orders ($592 thousand). Southern Research Institute, Sri International, and IIT Research Institute collectively represent the remaining 11% with one order each. All orders are unrestricted (no set-aside designations).
This vehicle is inactive and unsuitable for new business development. The ordering window closed over five years ago, and no recompete or successor vehicle is indicated in the source material.
Description
Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients
IDV awards
Latest task orders
Show all 14
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $691,527 | 59% |
| 2 | Mayo Clinic | $479,967 | 41% |
| 3 | Southern Research Institute | $5,752 | <1% |
| 4 | Sri International | $2,723 | <1% |
| 5 | IIT Research Institute | $1,010 | <1% |
"Minimum guarantee only" marks awardees whose obligations here are just the minimum order their contract guarantees.
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $1,180,979 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2026 | -$8,348 |
| FY2023 | $4,479 |
| FY2022 | $170,717 |
| FY2021 | $253,236 |
| FY2020 | $128,193 |
| FY2019 | $206,573 |
| FY2018 | $75,565 |
| FY2017 | $338,475 |
| FY2016 | $12,088 |
Quick answers
What is the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients contract vehicle?
Pharmacokinetic and Pharmacology Evaluations for Cancer Patients is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by National Institutes of Health (Department of Health and Human Services), awarded on July 1, 2016.
Which companies hold Pharmacokinetic and Pharmacology Evaluations for Cancer Patients?
5 companies hold Pharmacokinetic and Pharmacology Evaluations for Cancer Patients's IDV awards, one each. The latest went to Sri International on July 1, 2016. The awardees whose task orders obligated the most are University Of Pittsburgh - Of The Commonwealth System Of Higher Education, Mayo Clinic and Southern Research Institute.
How much has been spent through Pharmacokinetic and Pharmacology Evaluations for Cancer Patients?
14 task orders have been placed under Pharmacokinetic and Pharmacology Evaluations for Cancer Patients, obligating $1,180,979.
What is the shared ceiling of Pharmacokinetic and Pharmacology Evaluations for Cancer Patients?
Pharmacokinetic and Pharmacology Evaluations for Cancer Patients's shared ceiling is $9,900,000; its task orders have used 12% of it.
Which agencies use Pharmacokinetic and Pharmacology Evaluations for Cancer Patients the most?
The departments whose task orders under Pharmacokinetic and Pharmacology Evaluations for Cancer Patients obligated the most are Department of Health and Human Services ($1,180,979).
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle